| Market Capitalization (Millions $) |
130 |
| Shares
Outstanding (Millions) |
21 |
| Employees |
131 |
| Revenues (TTM) (Millions $) |
67 |
| Net Income (TTM) (Millions $) |
-105 |
| Cash Flow (TTM) (Millions $) |
44 |
| Capital Exp. (TTM) (Millions $) |
26 |
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc is a biotechnology company that specializes in developing small molecule drugs for infectious diseases, liver diseases, and cancer. The company was founded in 1995 and is located in Watertown, Massachusetts.
Enantaes main focus is on developing antiviral drugs for the treatment of hepatitis C virus (HCV) and respiratory syncytial virus (RSV). The companyes lead product, paritaprevir, is a protease inhibitor used in combination with other drugs to treat patients with chronic HCV infection. Paritaprevir is sold under the brand name VIEKIRA PAK by AbbVie Inc.
In addition to paritaprevir, Enanta has several other drugs in its pipeline for the treatment of HCV, such as EDP-514, a non-nucleoside polymerase inhibitor, and EDP-305, a farnesoid X receptor agonist.
Aside from HCV, Enanta is also developing drugs for RSV, a virus that causes respiratory infections in infants and older adults. The companyes lead RSV asset, EDP-938, is an orally bioavailable fusion inhibitor that is designed to prevent the virus from entering human cells. Enanta is currently conducting Phase 2a clinical trials on EDP-938.
Aside from its antiviral programs, Enanta is also developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease that is closely associated with obesity and diabetes. Enantaes lead NASH asset, EDP-305, is a farnesoid X receptor agonist that is designed to reduce liver inflammation and fibrosis. Enanta is currently conducting a Phase 2a clinical trial on EDP-30
Enanta has established collaborations with several major pharmaceutical companies, including AbbVie, Novartis, and Gilead Sciences. These collaborations provide the company with funding and expertise to advance its drug development programs.
Enanta Pharmaceuticals Inc has received numerous awards and recognitions for its drug development efforts, including the 2015 Technology of the Year Award by the Massachusetts Technology Leadership Council and the 2016 Biotech Pioneer Award by the Boston Business Journal.
Company Address: 4 Kingsbury Avenue Watertown 2472 MA
Company Phone Number: 607-0800 Stock Exchange / Ticker: NASDAQ ENTA
|
0.000%
0.72%